Advertisement

Parkinson’s Disease and Its Existing Therapy

  • P.-A. Fischer
Chapter
Part of the Milestones in Drug Therapy book series (MDT)

Abstract

The parkinsonian syndrome is characterized clinically by the motor symptoms akinesia, rigor, and resting tremor. These may occur concomitantly with mental disturbances and disorders of the autonomic nervous system. The degree and combination of the symptoms vary from case to case and during the course of the disease. With consideration of the motor signs of the disease, an akinetic-rigid and a tremor-dominant progress type is differentiated. Equal occurrence of akinesia, rigor, and tremor in one patient is designated as the equivalence type of parkinsonism.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kleist K. Beiträge zur Kenntnis der psychomotorischen Bewegungsstörungen. Zit nach K Kleist 1908; 1918.1Google Scholar
  2. 2.
    Kleist K. Zur Auffassung der subkortikalen Bewegungsstörungen (Chorea, Athetose, Bewegungsausfall, Starre, Zittern). Arch Psychiatr 1918; 59: 790–803.CrossRefGoogle Scholar
  3. 3.
    Naville F. Les complications et les sequelles mentales de L’encéphalite épidémique. Encéphale 1922; 17: 396–375, 423–436.Google Scholar
  4. 4.
    Albert ML, Feldmann RG, Willis AL. The subcortical dementia of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1974; 37: 121–130.CrossRefGoogle Scholar
  5. 5.
    Parkinson J. An Essay on the Shaking Palsy. Sherwood, Neely and Jones, London 1817.Google Scholar
  6. 6.
    Fischer P-A, editor. Spätsyndrome der Parkinson-Krankheit. Editiones Roche, Basel 1986.Google Scholar
  7. 7.
    Mayeux R. Mental State. In: Handbook of Parkinson’s Disease. Koller WC, editor. Dekker New York-Basel 1987: 127–144.Google Scholar
  8. 8.
    Russ M, Fischer P-A. Vergleichende testpsychologische Untersuchungen zur intellektuellen Leistungsfähigkeit von Parkinson-Patienten. Nervenarzt 1990; 61: 88–93.Google Scholar
  9. 9.
    Fischer P-A, editor. Vegetativstörungen beim Parkinson-Syndrom. Editiones Roche, Basel 1984.Google Scholar
  10. 10.
    Tanner CM, Goetz CG, Klawans HL. Autonomic nervous system disorders. In: Handbook of Parkinson’s Disease. Koller WC, editor. M. Dekker, New York 1987: 145–170.Google Scholar
  11. 11.
    Bateson MC, Gibber FB, Wilson RSE. Salivary Symptoms in Parkinson’s Disease. Arch Neurol 1973; 29: 274–275.CrossRefGoogle Scholar
  12. 12.
    Cros P, Parret J, Peyrin J, Freidel M, Dumas P. Sialorhées, apport des examens isotopiques. Revue Stomat Chir maxillofac 1979; 80/6: 319–324.Google Scholar
  13. 13.
    Hoehn MM, Yahr MD. Parkinsonism: Onset, Progression and Mortality. Neurology (Minneap.) 1967; 17: 427–442.CrossRefGoogle Scholar
  14. 14.
    Fischer P-A, Schneider E, Jacobi P. Verlaufsformen und Verlaufsfaktoren beim Parkinson-Syndrom. In: Parkinson-Syndrom. Kombinations- und Begleittherapien. Fischer P-A, editor. Schattauer Stuttgart-New York 1980: 97–115.Google Scholar
  15. 15.
    Jakob H. Neuropathologie des Parkinson-Syndroms und die Seneszenz des Gehirns. In: Langzeitbehandlung des Parkinson-Syndroms. Fischer P-A, editor. Schattauer Stuttgart-New York 1978: 5–25.Google Scholar
  16. 16.
    Birkmayer W, Riederer P. DieParkinson-Krankheit. 2. Aufl. Springer Wien-New York 1985.CrossRefGoogle Scholar
  17. 17.
    Fischer P-A, Schneider E, Jacobi P. Klinische Bilder des Parkinson-Syndroms und ihre Verläufe. In: Pathophysiologie Klinik und Therapie des Parkinsonismus. Gänshirt H, editor. Editiones Roche, Basel 1983: 51–65.Google Scholar
  18. 18.
    Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J. Increased life expectancy resulting from addition of L-deprenyl to madopar treatment in Parkinson’s disease: a longterm study. J Neural Transm 1985; 64: 113–127.CrossRefGoogle Scholar
  19. 19.
    Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson’s disease. Arch Neurol 1989a; 46: 1052–1060.CrossRefGoogle Scholar
  20. 20.
    Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease. New Engl J Med 1989b; 321: 1364–1371.CrossRefGoogle Scholar
  21. 21.
    Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease. Science 1989; 245: 519–522.Google Scholar
  22. 22.
    Birkmayer W, Hornykiewicz O. Der L-3,4-Dioxyphenyl-alanin (L-dopa) Effekt bei der Parkinson-Akinese. Wien Klin Wschr 1961; 73: 787–788.Google Scholar
  23. 23.
    Barbeau A, Murphy GS, Sourkes TL. Excretion of dopamine in diseases of basal ganglia. Science 1961; 133: 1706–1708.CrossRefGoogle Scholar
  24. 24.
    Fischer P-A, Schneider E, Jacobi P, Maxion H. Langzeitstudie zur Effektivität der L-Dopa-Therapie bei Parkinson-Kranken. Nervenarzt 1973; 44: 128–135.Google Scholar
  25. 25.
    Guillard A, Chanstang C. Maladie de Parkinson. Les facteurs de prognostic à long term. Rev Neurol 1978; 134: 341–354.Google Scholar
  26. 26.
    Marsden CD, Parkes JD. Success and problems of long-term Levodopa therapy in Parkinson’s disease. Lancet 1977; 1: 345–349.CrossRefGoogle Scholar
  27. 27.
    Yahr MD. Evaluation of Long-term-Therapy in Parkinson’s Disease: Mortality and Therapeutic Efficacy. In: Advances in Parkinsonism. Birkmayer W, Hornykiewicz O, editors. Roche, Basel 1976: 435–443.Google Scholar
  28. 28.
    Birkmayer W. Experimentelle Ergebnisse über die Kombinationsbehandlung des Parkin- son-Syndroms mit L-Dopa und einem Decarboxylase-Hemmer (Ro4–462). Wien Klin Wschr 1969; 81: 677–679.Google Scholar
  29. 29.
    Fischer P-A, Schneider E, Jacobi P, Maxion H. Kombinationsbehandlung des Parkin- son-Syndroms mit L-Dopa und Decarboxylase-Hemmer. Med Welt 1973; 24 (NF): 1742–1746.Google Scholar
  30. 30.
    Marsden CD, Parkes JD, Ress JE. Long-term-Treatment of Parkinson’s disease with an extracerebral dopa decarboxylase inhibitor (L-alpha-methyl-hydrazine. MK 486) and levodopa. Advances in Neurology 1973; 3: 79–93.Google Scholar
  31. 31.
    Poewe W. Klinik und Klassifikation der L-Dopa-induzierten Dyskinesien beim Parkin- son-Syndrom. Spätsyndrome der Parkinson-Krankheit. Fischer P-A, editor. Editiones Roche, Basel 1986: 257–265.Google Scholar
  32. 32.
    Poewe W, Lees AJ. The Pharmacology of Foot Dystonia in Parkinsonism. Clin Neu- ropharmacol 1987; 10: 47–56.Google Scholar
  33. 33.
    Erni W, Held K. The hydrodynamically balanced system: a novel principle of controlled drug release. Eur Neurol 1987; 27 (suppl. 1): 21–27.CrossRefGoogle Scholar
  34. 34.
    Yeh KC, August TE, Bush DF et al. Pharmacokinetics and bioavailability of Sinemet CR: A summary of human studies. Neurology 1989; 39: 25–38.CrossRefGoogle Scholar
  35. 35.
    Hornykiewicz O. The mechanism of action of L-dopa in Parkinson’s Disease. Life Sci 1974; 15: 1249–1259.CrossRefGoogle Scholar
  36. 36.
    Hornykiewicz O. Bedeutung von cerebralen Neurotransmitter-Wechselwirkungen für das Parkinson-Syndrom. In: Parkinson-Syndrom: Kombinations- und Begleit-Therapien. Fischer P-A, editor. Schattauer Verlag Stuttgart-New York 1980: 5–25.Google Scholar
  37. 37.
    Nutt JG, Woodward WR, Carter JH, Trotmann TL. Influence of fluctuations of plasma large neutral amino acids with normal diets on the clinical response to levodopa. J Neurol Neurosurg Psychiatry 1989; 52: 481–487.CrossRefGoogle Scholar
  38. 38.
    Yahr MD. Aspekte zur Pathogenese und Behandlung des Parkinsonismus. In: L-Dopa- Substitution der Parkinson-Krankheit. RiedererP, Umek H, editors. Springer Wien-New York 1985: 97–104.CrossRefGoogle Scholar
  39. 39.
    Schneider E, Fischer P-A, Jacobi P, Grotz A. Exogene Psychosen beim Parkinson-Syndrom. Häufigkeit und Entstehungs-bedingungen. Fortschr Neurol Psychiat 1984; 52: 207–214.CrossRefGoogle Scholar
  40. 40.
    Calne DB, Teychenne PF, Claveria LE, Eastman R, Greenacre JK, Petrie A. Bromocriptine in parkinsonism. Br Med J 1974; 4: 442–444.CrossRefGoogle Scholar
  41. 41.
    Fischer P-A, Frieling B, editors. Morbus Parkinson — Neue Möglichkeiten mit Lisurid. W de Gruyter, Berlin, 1989.Google Scholar
  42. 42.
    Jankovic J. Long-term-study of pergolide in Parkinson’s disease. Neurology 1985; 35: 296–299.CrossRefGoogle Scholar
  43. 43.
    Lees AJ, Stern GM. Sustained bromocriptine therapy in previously untreated patients with Parkinson’s Disease. J Neurol Neurosurg a Psychiatry 1981; 44: 1020–1023.CrossRefGoogle Scholar
  44. 44.
    Schneider E, Fischer P-A. Bromocriptin in der Behandlung der fortgeschrittenen Stadien des Parkinson-Syndroms. Dtsch med Wschr 1982; 107: 175–179.CrossRefGoogle Scholar
  45. 45.
    Fischer P-A, Przuntek H, Majer M, Welzel D. Kombinations-behandlung früher Stadien des Parkinson-Syndroms mit Bromocriptin und Levodopa. Ergebnisse einer multizentrischen Studie. Dtsch Med Wschr 1984; 109: 1279–1283.CrossRefGoogle Scholar
  46. 46.
    Rinne UK. The importance of an early combination of a dopamine agonist levodopa in the treatment of Parkinson’s disease. In: Lisuride: A New Dopamine Agonist and Parkinson’s Disease, van Hanen J, Rinne UK, editors. Excerpta Medica, Amsterdam 1986: 64–71.Google Scholar
  47. 47.
    Rinne UK. Combined bromocriptine-levodopa therapy early in Parkinson’s disease — a 5 years follow up. Neurol 1987; 37: 826–828.CrossRefGoogle Scholar
  48. 48.
    Rinne UK. Lisuride, a dopamine agonist in the treatment of early Parkinson’s disease. Neurol 1989; 39: 336–339.CrossRefGoogle Scholar
  49. 49.
    Schwab RS, England AC, Poskanzer DC, Young RR. Amantadine in the treatment of Parkinson’s Disease. JAMA 1969; 1168–.Google Scholar
  50. 50.
    Wesemann W. Aspekte zum Wirkungsmechanismus von Amantadinen. In: Amantadin Workshop. Danielczyk W, Wesemann W, editors. Edition Materia Medica Gräfelfing 1984: 15–23.Google Scholar
  51. 51.
    Kornhuber J, Bormann J, Retz W, Hübers M, Riederer P. Memantine displaces MK-801 at therapeutic concentrations in postmortem human frontal cortex. European Journal of Pharmacology 1989; 166: 589–590.CrossRefGoogle Scholar
  52. 52.
    Ordenstein L. Sur la paralysis agitante et la Sclérose en plaques généralisée. Doctoral Thesis, Martinet, Paris 1987.Google Scholar
  53. 53.
    Duvoisin RC. Cholinergic-anticholinergic antagonism in parkinsonism. Archives of Neurology 1967; 17: 124–136.CrossRefGoogle Scholar
  54. 54.
    Lloyd KG. Neurochemical compensation in Parkinson’s Disease. In: Parkinson’s Disease, concepts and prospects. Lakke JPF, Korf J, Wesseling H, editors. Excerpta Medica Amsterdam-Oxford 1977: 61–72.Google Scholar
  55. 55.
    Syndulko K, Gilden ER, Hansch EC, Potvin AA, Tourtellotte WW, Potvon JH. Decreased verbal memory associates with anti-cholinergic treatment in Parkinson’s disease. Internat J Neurosci 1981; 14: 61–66.CrossRefGoogle Scholar
  56. 56.
    Johnston JP. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 1968; 17: 1285–1297.CrossRefGoogle Scholar
  57. 57.
    Riederer P, Konradi C, Schay K, Wenziel W, Birkmayer G, Danielczyk W, Sofic E, Youdim MBH. Localization of MAO-A- and MAO-B in Human Brain: A Step in Understanding the Therapeutic Action of L-Deprenyl. In: Parkinson’s Disease. Yahr MD, Bergmann KJ, editors. Raven Press, New York 1987: 111–118.Google Scholar
  58. 58.
    Birkmayer W, Riederer P, Youdim MBH. The potentiation of the antiakinetic effect of L-dopa treatment by an inhibitor of MAO-B, deprenyl. J Neural Transm 1975; 36: 303–326.CrossRefGoogle Scholar
  59. 59.
    Spiegel EA, Wycis HT, Marks M, Lee AJ. Stereotaxic apparatus for operations on the human brain. Science 1947; 106: 349–350.CrossRefGoogle Scholar
  60. 60.
    Mundinger F. 30 Jahre stereotaktische Hirnoperationen beim Parkinsonismus. In: Pathophysiologic, Klinik und Therapie des Parkinsonismus. Gänshirt H, editor. Editiones Roche, Basel 1983: 331–357.Google Scholar
  61. 61.
    Lindvall O, Brundin P, Widner H, Rehncrona S, Gustavii B, Frakkoviak R, Leenders K, Sawle G, Rothell JC, Marsden CD, Björklund A. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson’s disease. Science 1990; 247: 574–577.CrossRefGoogle Scholar
  62. 62.
    Lindvall O, Rehncrona S, Brundin P, Gustavii B, Astedt B, Widner H, Lindholm T, Björklund A, Leenders K, Rothwell JC, Frackowiak F, Marsden CD, Johnels B, Steg G, Freedman R, Barry JH, Seiger A, Bygdeman M, Strömberg I, Olson L. Human fetal dopamine neurons grafted into the striatum of two patients with severe Parkinson’s disease. A detailed account of methodology and a 6-months follow up. Arch Neurol 1989; 46: 615–631.CrossRefGoogle Scholar
  63. 63.
    Lindvall O. Transplantation into the human brain: present status and future possibilities. J Neurol Neurosurg Psychiatry 1989; (spec, supp.): 39–54 1.CrossRefGoogle Scholar
  64. 64.
    Oertel W, Kupsch A. Transplantation von Dopamin-synthetisierenden Zellen und trophische Faktoren — zukünftige Behandlungsverfahren des idiopathischen Parkinson-Syndroms? In: Parkinson-Syndrom und Nigra-Prozesse. Fischer P-A, editor. Editiones Roche, Basel 1991: 207–241.Google Scholar
  65. 65.
    Fahn St, Bressmann SB. Should Levodopa therapy for Parkinsonism be started early or late? Evidence against early treatment. Can J Neurol Sci 1984; 11: 200–206.Google Scholar
  66. 66.
    Fischer P-A. Aktuelle Parkinson-Therapie: Heutiges Konzept für die Anwendung von L-Dopa. Akt Neurol 1988; 15: 38–41.CrossRefGoogle Scholar
  67. 67.
    Markham CH, Diamond SG. Evidence of support early Levodopa therapy in Parkinson’s disease. Neurology 1981; 31: 125–131.CrossRefGoogle Scholar
  68. 68.
    Muenter MD. Should Levodopa therapy be started early or late? Can J Neurol Sci 1984; 11: 195 – 199Google Scholar
  69. 69.
    Rinne UK. Combination of a dopamine agonist, MAO-B inhibitor and Levodopa — a new strategy in the treatment of early Parkinson’s disease. Acta Neurol Scand 1989; 126: 165–169.CrossRefGoogle Scholar
  70. 70.
    Birkmayer W, Riederer P, Youdim MBH. Distinction between benign and malignant type of Parkinson’s disease. Clin Neurol Neusurg 1979; 158: 81–83.Google Scholar
  71. 71.
    Fischer P-A, Jacobi P, Schneider E, Maxion H. Correlation between Clinical and CT-Findings in Parkinson’s Syndrome. In: Computerized Tomography. Lanksch N, Kazner E, editors. Springer Berlin-Heidelberg-New York-Tokyo 1976: 244–248.Google Scholar
  72. 72.
    Schneider E, Becker H, Fischer P-A, Grau H, Jacobi P. The course of brain atrophy in Parkinson’s disease. Arch Psychiat Nervenkr 1979; 227: 89–95.CrossRefGoogle Scholar
  73. 73.
    Schneider E, Fischer P-A, Jacobi P, Becker H, Beyer M. Cerebral atrophy and long-term response to Levodopa in Parkinson’s disease. J Neurol 1979; 222: 37–43.CrossRefGoogle Scholar
  74. 74.
    Fischer P-A, editor. Parkinson plus. Zerebrale Polypathie beim Parkinson-Syndrom. Springer-Heidelberg-New York-Tokyo 1984: 159. 1Google Scholar
  75. 75.
    Fischer P-A. Long-term course in Parkinson’s syndrome and cerebral polypathy (Parkinson plus). Raven Press, New York, Adv Neurol 1987; 45: 235–238.Google Scholar
  76. 76.
    Fahn St. Secondary Parkinsonism. In: Scientific approaches to Clinical Neurology. Goldensohn ES, Appel SH, editors. Lea and Febinger, Philadelphia 1977: 1159–1189.Google Scholar

Copyright information

© Springer Basel AG 1993

Authors and Affiliations

  • P.-A. Fischer

There are no affiliations available

Personalised recommendations